The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness.
Marketed Covid-19 vaccines and those in late-stage development generally target only the SARS-CoV-2 spike protein. These vaccines are easier to develop, but sensitive to viral mutations allowing immune escape. Mutations are already starting to accumulate in the spike protein that may impair neutralizing antibody responses to these vaccines.
The objective of our vaccine is to activate a strong humoral and cellular immune response targeting multiple parts of the SARS-CoV-2 virus. The multi-specific immune response will function by limiting the spread of the infection and eliminating infected cells.
The design of our vaccine targets three proteins of the SARS-CoV-2 virus (spike, membrane and nucleoprotein) thereby activating a broadly reactive immune response to the virus that will curb immune escape. Our unique synthetic whole virus vaccine induces neutralizing antibodies, and broadly reactive CD4+ and CD8+ T cell responses important to offer adequate protection against disease caused by SARS-CoV-2 viruses.